Targeting Lymphatic Vessel Activation and CCL21 Production by Vascular Endothelial Growth Factor Receptor-3 Inhibition Has Novel Immunomodulatory and Antiarteriosclerotic Effects in Cardiac Allografts | Zendy

Antti I. Nykänen | Zendy; H. Sandelin | Zendy; R. Krebs | Zendy; Mikko Keränen | Zendy; Raimo Tuuminen | Zendy; Terhi Kärpänen | Zendy; Yan Wu | Zendy; Bronislaw Pytowski | Zendy; Petri Koskinen | Zendy; Seppo YläHerttuala | Zendy; Kari Alitalo | Zendy; Karl Lemström | Zendy

Open Access

Targeting Lymphatic Vessel Activation and CCL21 Production by Vascular Endothelial Growth Factor Receptor-3 Inhibition Has Novel Immunomodulatory and Antiarteriosclerotic Effects in Cardiac Allografts

Author(s) -

Antti I. Nykänen,

H. Sandelin,

R. Krebs,

Mikko Keränen,

Raimo Tuuminen,

Terhi Kärpänen,

Yan Wu,

Bronislaw Pytowski,

Petri Koskinen,

Seppo YläHerttuala,

Kari Alitalo,

Karl Lemström

Publication year - 2010

Publication title -

circulation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.795

H-Index - 607

eISSN - 1524-4539

pISSN - 0009-7322

DOI - 10.1161/circulationaha.109.910703

Subject(s) - lymphangiogenesis , medicine , lymphatic system , foxp3 , vascular endothelial growth factor , vascular endothelial growth factor c , chemokine , immunology , immune system , ccl21 , cancer research , pathology , vascular endothelial growth factor a , chemokine receptor , cancer , metastasis , vegf receptors

Lymphatic network and chemokine-mediated signals are essential for leukocyte traffic during the proximal steps of alloimmune response. We aimed to determine the role of lymphatic vessels and their principal growth signaling pathway, vascular endothelial growth factor (VEGF)-C/D/VEGFR-3, during acute and chronic rejection in cardiac allografts.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research